Intra-Cellular Therapies Inc. Daily Stock Analysis

Daily Stock Analysis, ITCI, Intra-Cellular Therapies Inc, priceseries

Intra-Cellular Therapies Inc. Daily Stock Analysis
Stock Information
Open
54.85
Close
53.23
High
55.00
Low
52.11
Previous Close
55.09
Daily Price Gain
-1.86
YTD High
59.88
YTD High Date
Mar 2, 2022
YTD Low
38.51
YTD Low Date
Jan 21, 2022
YTD Price Change
1.21
YTD Gain
2.33%
52 Week High
59.88
52 Week High Date
Mar 2, 2022
52 Week Low
28.40
52 Week Low Date
Aug 12, 2021
52 Week Price Change
19.91
52 Week Gain
59.75%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Mar 8. 2017
14.16
Mar 20. 2017
14.88
8 Trading Days
5.06%
Link
LONG
Jun 13. 2017
10.13
Jul 6. 2017
12.28
16 Trading Days
21.18%
Link
LONG
Aug 28. 2017
15.70
Sep 14. 2017
19.67
12 Trading Days
25.31%
Link
LONG
Jan 3. 2018
15.47
Jan 25. 2018
17.98
15 Trading Days
16.21%
Link
LONG
Feb 12. 2018
16.93
Feb 28. 2018
19.42
11 Trading Days
14.73%
Link
LONG
May 11. 2018
20.35
Jun 4. 2018
22.04
15 Trading Days
8.33%
Link
LONG
Jul 5. 2018
18.92
Jul 27. 2018
20.77
16 Trading Days
9.80%
Link
LONG
Jan 4. 2019
11.88
Jan 17. 2019
12.76
9 Trading Days
7.44%
Link
LONG
Feb 1. 2019
12.14
Feb 21. 2019
13.05
13 Trading Days
7.52%
Link
LONG
Jun 12. 2019
11.82
Jun 20. 2019
13.00
6 Trading Days
9.97%
Link
LONG
Oct 25. 2019
8.72
Nov 7. 2019
9.40
9 Trading Days
7.84%
Link
LONG
Dec 3. 2019
9.71
Jan 8. 2020
27.64
24 Trading Days
184.65%
Link
LONG
May 5. 2020
17.89
May 26. 2020
22.05
14 Trading Days
23.26%
Link
LONG
Jun 15. 2020
21.56
Jul 2. 2020
24.45
13 Trading Days
13.42%
Link
LONG
Dec 15. 2020
26.50
Jan 20. 2021
32.40
23 Trading Days
22.28%
Link
LONG
May 6. 2021
33.43
Jun 2. 2021
38.63
18 Trading Days
15.55%
Link
LONG
Aug 27. 2021
31.43
Sep 10. 2021
33.49
9 Trading Days
6.54%
Link
LONG
Dec 17. 2021
39.16
Jan 4. 2022
47.07
11 Trading Days
20.20%
Link
LONG
Jan 21. 2022
42.66
Feb 23. 2022
52.95
22 Trading Days
24.11%
Link
Company Information
Stock Symbol
ITCI
Exchange
NasdaqGS
Company URL
http://www.intracellulartherapies.com
Company Phone
212-923-3344
CEO
Sharon Mates
Headquarters
New York
Business Address
430 EAST 29TH STREET, NEW YORK, NY 10016
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001567514
About

Intra-Cellular Therapies, Inc. is a biopharmaceutical company, which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. Its lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. The company also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease, and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. Intra-Cellular Therapies was founded by Paul Greengard on August 29, 2013 and is headquartered in New York, NY.

Description

Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease. The company is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, depression, and other neuropsychiatric and neurological disorders. Lumateperone, a molecule, is in Phase III clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer's disease. The company is also utilizing its phosphodiesterase platform and other proprietary chemistry platforms to develop drugs for the treatment of central nervous system and other disorders. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading